Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III crossover study of N-acetyl-L-leucine in CACNA1A disorders
2025-523828-51-00Phase 3Authorised
- Sponsor
- IntraBio
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of levacetylleucine in CACNA1A-related channelopathy (CACNA1A-RD) (2 arms), sponsored by IntraBio. Primary endpoint: Scale for the Assessment and Rating of Ataxia. Planned start Aug 2026; status: authorised.
02
Drugs
levacetylleucine
03
Conditions
CACNA1A-related channelopathy (CACNA1A-RD)
Beyond the preview
Go deeper on 2025-523828-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523828-51-00.